Tower Research Capital LLC (TRC) - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 114 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q3 2023$19,304
+18.0%
9,509
+33.7%
0.00%0.0%
Q2 2023$16,358
+54426.7%
7,112
-27.4%
0.00%0.0%
Q1 2023$30
-14.3%
9,792
-33.9%
0.00%0.0%
Q4 2022$35
-99.8%
14,818
+39.2%
0.00%
Q3 2022$21,000
-51.2%
10,648
-33.5%
0.00%
-100.0%
Q2 2022$43,000
+38.7%
16,023
+51.5%
0.00%
Q1 2022$31,000
+82.4%
10,573
+129.3%
0.00%
Q4 2021$17,000
-32.0%
4,610
-20.0%
0.00%
-100.0%
Q3 2021$25,000
-3.8%
5,762
-33.0%
0.00%0.0%
Q2 2021$26,000
+73.3%
8,606
+93.5%
0.00%
Q1 2021$15,000
-6.2%
4,448
-2.8%
0.00%
Q4 2020$16,000
+14.3%
4,578
+4.0%
0.00%
Q3 2020$14,000
-33.3%
4,403
-61.2%
0.00%
-100.0%
Q2 2020$21,000
+75.0%
11,344
-7.3%
0.00%0.0%
Q1 2020$12,00012,243
+12143.0%
0.00%
Q4 2019$0
-100.0%
100
-99.7%
0.00%
-100.0%
Q3 2019$59,000
+490.0%
38,789
+710.8%
0.00%
+300.0%
Q2 2019$10,000
-64.3%
4,784
-37.4%
0.00%
-50.0%
Q1 2019$28,000
-28.2%
7,645
-25.1%
0.00%
-33.3%
Q4 2018$39,000
+160.0%
10,209
+553.6%
0.00%
+200.0%
Q3 2018$15,000
+200.0%
1,562
+119.4%
0.00%
Q2 2018$5,000
-61.5%
712
-72.1%
0.00%
-100.0%
Q1 2018$13,000
-74.5%
2,548
-69.2%
0.00%
-75.0%
Q3 2017$51,000
+37.8%
8,283
-19.0%
0.00%0.0%
Q2 2017$37,000
+131.2%
10,226
+110.9%
0.00%
+100.0%
Q1 2017$16,000
-23.8%
4,849
-44.0%
0.00%0.0%
Q4 2016$21,000
+320.0%
8,652
+487.8%
0.00%
Q3 2016$5,000
-37.5%
1,472
-35.5%
0.00%
-100.0%
Q2 2016$8,000
-68.0%
2,282
-63.2%
0.00%
-75.0%
Q1 2016$25,000
-28.6%
6,195
-19.2%
0.00%
-33.3%
Q4 2015$35,000
+9.4%
7,666
+44.6%
0.01%
+100.0%
Q3 2015$32,0005,3000.00%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q4 2022
NameSharesValueWeighting ↓
Two Seas Capital LP 825,569$3,211,0002.46%
GREAT POINT PARTNERS LLC 668,907$2,602,0000.58%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 270,000$1,050,0000.47%
QCM Cayman, Ltd. 10,205$40,0000.24%
Pitti Group Wealth Management, LLC 50,000$195,0000.22%
RTW INVESTMENTS, LP 2,504,493$9,742,0000.14%
Hudson Bay Capital Management LP 1,805,700$7,024,0000.07%
Quinn Opportunity Partners LLC 276,485$1,076,0000.07%
Kepos Capital LP 200,000$778,0000.06%
XTX Topco Ltd 29,026$113,0000.06%
View complete list of ARBUTUS BIOPHARMA CORP shareholders